lopinavir/ritonavir accord 200 mg/50 mg apvalkotās tabletes
accord healthcare b.v., netherlands - lopinavirum, ritonavirum - apvalkotā tablete - 200 mg/50 mg
glopenel 75 mg apvalkotās tabletes
pharmathen s.a., greece - klopidogrels - apvalkotā tablete - 75 mg
lopinavir/ritonavir sandoz 200 mg/50 mg apvalkotās tabletes
sandoz d.d., slovenia - lopinavirum, ritonavirum - apvalkotā tablete - 200 mg/50 mg
trombex 75 mg apvalkotās tabletes
zentiva, k.s., czech republic - klopidogrels - apvalkotā tablete - 75 mg
darunavir sandoz 800 mg apvalkotās tabletes
sandoz d.d., slovenia - darunavīrs - apvalkotā tablete - 800 mg
darunavir sandoz 400 mg apvalkotās tabletes
sandoz d.d., slovenia - darunavīrs - apvalkotā tablete - 400 mg
darunavir sandoz 600 mg apvalkotās tabletes
sandoz d.d., slovenia - darunavīrs - apvalkotā tablete - 600 mg
lopinavir/ritonavir ranbaxy 100 mg/25 mg apvalkotās tabletes
ranbaxy uk ltd., united kingdom - lopinavirum, ritonavirum - apvalkotās tabletes - 100 mg/25 mg
platel 75 mg apvalkotās tabletes
medochemie ltd., cyprus - klopidogrels - apvalkotā tablete - 75 mg
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.